The Clinical Pharmacology and Analyfical Chemistry (CPAC) Core contains clinical pharmacology expertise with a CLIA-certified laboratory to support clinical and preclinical HIV/AIDS research among CFAR invesfigators at UNC, FHl, and RTI. Since the CPAC Core is the only one of its kind within the CFAR system, it also supports a growing number of invesfigators in other CFARs across the country. The CPAC Core consists of experienced scientists who provide a high level of expertise in trial design, development and validation of analytical methods in complex biological matrices to accurately quantify drug exposure, and interpretation of preclinical and clinical pharmacology data. The CPAC Core also provides leadership in HIV prevention strategies, women's health issues, and international pharmacology, and trains domestic and international investigators in pharmacologic and analytic methods.
A major feature of controlling the HIV epidemic is the complex interplay between drug exposure and response in treatment, prevention, and cure. This is evidenced in the extensive preclinical and early clinical dose-response investigations during drug development. Optimizing effective therapy in any of these areas of the epidemic requires extensive knowledge of exposure targets and pharmacokinefics in multiple body compartments to chose the best doses, dosing frequencies, and drug combinations for efficacy. The CPAC Core provides the necessary resources for CFAR users to optimize their preclinical and clinical research approach.
|White, Becky L; Walsh, Joan; Rayasam, Swati et al. (2015) What Makes Me Screen for HIV? Perceived Barriers and Facilitators to Conducting Recommended Routine HIV Testing among Primary Care Physicians in the Southeastern United States. J Int Assoc Provid AIDS Care 14:127-35|
|Jennings, Larissa; Rompalo, Anne M; Wang, Jing et al. (2015) Prevalence and correlates of knowledge of male partner HIV testing and serostatus among African-American women living in high poverty, high HIV prevalence communities (HPTN 064). AIDS Behav 19:291-301|
|Rosen, David L; Golin, Carol E; Grodensky, Catherine A et al. (2015) Opt-out HIV testing in prison: informed and voluntary? AIDS Care 27:545-54|
|Evon, Donna M; Golin, Carol E; Bonner, Jason E et al. (2015) Adherence during antiviral treatment regimens for chronic hepatitis C: a qualitative study of patient-reported facilitators and barriers. J Clin Gastroenterol 49:e41-50|
|Joseph, Sarah B; Arrildt, Kathryn T; Sturdevant, Christa B et al. (2015) HIV-1 target cells in the CNS. J Neurovirol 21:276-89|
|Edwards, Jessie K; Cole, Stephen R; Adimora, Adaora et al. (2015) Illustration of a measure to combine viral suppression and viral rebound in studies of HIV therapy. J Acquir Immune Defic Syndr 68:241-4|
|Onsomu, Elijah O; Abuya, Benta A; Okech, Irene N et al. (2015) Association between domestic violence and HIV serostatus among married and formerly married women in Kenya. Health Care Women Int 36:205-28|
|O'Shea, Michele S; Rosenberg, Nora E; Hosseinipour, Mina C et al. (2015) Effect of HIV status on fertility desire and knowledge of long-acting reversible contraception of postpartum Malawian women. AIDS Care 27:489-98|
|Cole, Stephen R; Lau, Bryan; Eron, Joseph J et al. (2015) Estimation of the standardized risk difference and ratio in a competing risks framework: application to injection drug use and progression to AIDS after initiation of antiretroviral therapy. Am J Epidemiol 181:238-45|
|Rahangdale, Lisa; De Paris, Kristina; Kashuba, Angela D M et al. (2015) Immunologic, virologic, and pharmacologic characterization of the female upper genital tract in HIV-infected women. J Acquir Immune Defic Syndr 68:420-4|
Showing the most recent 10 out of 624 publications